China Signals More Antitrust Scrutiny for Drugmakers Over Prices

Chinese regulators are closely examining the pricing methods of local and foreign drugmakers for any antitrust violations, according to a state-run financial newspaper, as the government conducts a wide-ranging campaign to regulate prices of medicines.

Antitrust watchdogs are looking for violations such as price manipulation among competitors or via the distribution chain, according to a report by the Securities Times, which cited a recent speech in Shanghai by Lu Yanchun, deputy head of the National Development and Reform Commission’s price supervision and anti-monopoly bureau.